LORAZEPAM | N018140 | HIKMA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Emily Robin et al FDA-2010-P-0091 · 6 docket documents Emily Robin and other individuals who experienced adverse reactions to benzodiazepines filed this petition requesting that the FDA amend labeling for all FDA-approved benzodiazepines, including Ativan (lorazepam), Xanax (alprazolam), Klonopin (clonazepam), and Valium (diazepam), to standardize warni | Other | 2010-03-01 | Denied | Emily Robin et al |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.93
per ml
Lowest NADAC/Unit
$1.93
per ml
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00641604825LORAZEPAM 2 MG/ML VIAL | $1.93 | ML | Generic | — | 2026-06-17 |
| 00641620725LORAZEPAM 2 MG/ML VIAL | $1.93 | ML | Generic | — | 2026-06-17 |
| 72572038025LORAZEPAM 2 MG/ML VIAL | $1.93 | ML | Generic | — | 2026-06-17 |
| 00641604425LORAZEPAM 2 MG/ML VIAL | $1.93 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.